Título:	Molecular and cellular biomarkers of COVID-19 prognosis : protocol for the prospective cohort TARGET study
Autor(es):	Kurizky, Patricia Shu Nóbrega, Otávio T. Soares, Alexandre Anderson de Sousa Munhoz Aires, Rodrigo Barbosa Albuquerque, Cleandro Pires de Nicola, André Moraes Andrade, Patrícia Albuquerque de Carvalho, Andréa Teixeira Naves, Luciana Ansaneli Fontes, Wagner Luz, Isabelle Souza Felicori, Liza Gomides, Ana Paulo Monteiro Silva, Dayde Lane Mendonça Espindola, Laila Salmen Martins Filho, Olindo Assis Lima, Sheila Maria Barbosa de Mota, Licia Maria Henrique Gomes, Ciro Martins
Assunto:	Covid-19 Citocinas Tromboelastometria Proteômica Metabolômica Biomarcadores Imunologia Sistema imunológico Genética
Data de publicação:	4-Mar-2021
Editora:	JMIR Publications
Referência:	KURIZKY, Patricia et al. Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study. JMIR Research Protocols, v. 10, p. e24211, 2021. DOI: dx.doi.org/10.2196/24211. Disponível em: https://www.researchprotocols.org/2021/3/e24211. Acesso em: 14 abr. 2021.
Abstract:	Background: Since the beginning of the COVID-19 pandemic, the world’s attention has been focused on better understanding the relation between the human host and the SARS-CoV-2 virus, as its action has led to hundreds of thousands of deaths. Objective: In this context, we decided to study certain consequences of the abundant cytokine release over the innate and adaptive immune systems, inflammation, and hemostasis, comparing mild and severe forms of COVID-19. Methods: To accomplish these aims, we will analyze demographic characteristics, biochemical tests, immune biomarkers, leukocyte phenotyping, immunoglobulin profile, hormonal release (cortisol and prolactin), gene expression, thromboelastometry, neutralizing antibodies, metabolic profile, and neutrophil function (reactive oxygen species production, neutrophil extracellular trap production, phagocytosis, migration, gene expression, and proteomics). A total of 200 reverse transcription polymerase chain reaction–confirmed patients will be enrolled and divided into two groups: mild/moderate or severe/critical forms of COVID-19. Blood samples will be collected at different times: at inclusion and after 9 and 18 days, with an additional 3-day sample for severe patients. We believe that this information will provide more knowledge for future studies that will provide more robust and useful clinical information that may allow for better decisions at the front lines of health care. Results: The recruitment began in June 2020 and is still in progress. It is expected to continue until February 2021. Data analysis is scheduled to start after all data have been collected. The coagulation study branch is complete and is already in the analysis phase.
Unidade Acadêmica:	Faculdade de Medicina (FMD)
Licença:	©Patricia Kurizky, Otávio T Nóbrega, Alexandre Anderson De Sousa Munhoz Soares, Rodrigo Barbosa Aires, Cleandro Pires De Albuquerque, André Moraes Nicola, Patrícia Albuquerque, Andréa Teixeira-Carvalho, Luciana Ansaneli Naves, Wagner Fontes, Isabelle Souza Luz, Liza Felicori, Ana Paulo Monteiro Gomides, Dayde Lane Mendonça-Silva, Laila Salmen Espindola, Olindo Assis Martins-Filho, Sheila Maria Barbosa de Lima, Licia Maria Henrique Mota, Ciro Martins Gomes. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 04.03.2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.
DOI:	dx.doi.org/10.2196/24211
Aparece nas coleções:	Artigos publicados em periódicos e afins UnB - Covid-19

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.